
Dr Peddi on Navigating Disease Progression in HR+/HER2− Breast Cancer
Disease progression rate and emerging ESR1 alterations help guide subsequent treatment decisions in HR+/HER2− breast cancer.
Treatment selection following progression on a CDK4/6 inhibitor in hormone receptor–positive (HR+)/HER2− breast cancer increasingly involves molecular testing and individualized assessment of disease behavior. Although CDK4/6 inhibitors have become an important component of treatment, determining the next therapeutic approach requires consideration of emerging genomic alterations, disease progression rates, and patient symptoms.
During the 44th Annual
According to Peddi, although patients may experience several years of benefit from CDK4/6 inhibitor-based treatment, disease progression remains a common challenge. He notes that approximately 50% of patients experience progression after the second year of treatment, raising important questions about how clinicians should approach subsequent therapy.
One area that has changed treatment decision-making is the ability to evaluate molecular alterations through ctDNA testing, particularly alterations involving ESR1. Rather than relying exclusively on radiographic imaging to identify disease progression, clinicians can increasingly assess molecular changes that may help inform treatment selection.
Peddi explains that ctDNA assessment of ESR1 status is now becoming part of this process, providing another approach to evaluating patients and identifying molecular changes that may influence subsequent treatment selection.
For patients experiencing rapid disease progression, particularly within approximately 6 months, and who are also symptomatic, Peddi says clinicians may need to move more quickly toward chemotherapy options, including antibody-drug conjugates. In these circumstances, the urgency of controlling disease progression becomes an important consideration when selecting treatment.
Conversely, patients experiencing a slower relapse may have more time for additional molecular evaluation and consideration of available treatment targets. For example, patients whose disease progresses 4 or 5 years after initiating CDK4/6 inhibitor therapy may have a longer window in which clinicians can evaluate their molecular profile and determine the most appropriate subsequent treatment.
As additional molecular testing strategies become incorporated into clinical practice, understanding both the genomic characteristics of a patient's disease and its rate of progression will remain important when selecting subsequent therapies. Peddi emphasizes that identifying the next best treatment requires clinicians to consider the available molecular information alongside the patient's clinical presentation and the pace of disease progression.
Related to this article







